TREAT: Implications for Guideline Updates and Clinical Care

American Journal of Kidney Diseases

Volumn 55, Issue 6, 2010, Pages 984-987

  Levin, Adeera ^a   Beaulieu, Monica Carol ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG MEGADOSE; EDITORIAL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; IRON DEFICIENCY; IRON DEPLETION; IRON THERAPY; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS;

EID: 77952580964     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.03.006     Document Type: Editorial

References (14)

1. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 12 (1989) 992-1000
2. Muirhead N., Bargman J., Burgess E., et al. Evidence-based recommendations for the clinical use of recombinant erythropoietin. Am J Kidney Dis 26 2 suppl 1 (1995) S1-S24
3. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 9 (1998) 584-590
4. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with CKD and anemia. N Engl J Med 355 20 (2006) 2071-2084
5. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 20 (2006) 2085-2098
6. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 3 (2007) 471-530
7. Barrett B.J., Fenton S.S., Ferguson B., et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 10 suppl 13 (1999) S292-S296
8. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 21 (2009) 2019-2032
9. Roger S.D., McMahon L.P., Clarkson A., et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15 1 (2004) 148-156
10. Levin A., Djurdjev O., Thompson C.R., et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with chronic kidney disease. Am J Kidney Dis 46 5 (2005) 799-811
11. Macdougall I.C., Temple M., and Kwan J.T.C. Is early treatment of anaemia with epoetin alfa beneficial to predialysis chronic kidney disease patients?. Results of a multicentre, open-label, prospective, randomised, comparative group trial. Nephrol Dial Transplant 22 3 (2007) 684-686
12. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 3 (2000) 1325-1335
13. Parfrey P.S., Foley R.N., Wittreich B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 7 (2005) 2180-2189
14. Yee J., Zasuwa G., Frinak S., and Besarab A. Hemoglobin variability and hyporesponsiveness: much ado about something or nothing?. Adv Chronic Kidney Dis 16 2 (2009) 83-93